Skip to Main Content

Biogen (BIIB) said Monday that it has signed a deal with Dublin-based Alkermes (ALKS) to develop and market a drug in late-stage clinical trials to treat relapsing forms of multiple sclerosis.

Under the agreement, Biogen will receive an exclusive, worldwide license to market the experimental oral medicine, called ALKS 8700, and will pay Alkermes a royalty on worldwide scales in the mid-teens.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!